MEPs add their voice to protest at patent for breast cancer geneBMJ 2001; 323 doi: https://doi.org/10.1136/bmj.323.7318.888 (Published 20 October 2001) Cite this as: BMJ 2001;323:888
- Rory Watson
The European parliament has added its support to critics of the move to grant two patents in Europe to Myriad Genetics of Salt Lake City, Utah, for a test to screen for predisposition to breast cancer.
The decision taken in January and May this year by the European Patent Office, based in Munich, to grant the patents is already being opposed by the French ministries of health and research and the Institut Curie, France's leading cancer research centre (15 September, p 589).
MEPs in Strasbourg earlier this month adopted a resolution warning that the patents, following …